mirМИР (Модернизация. Инновации. Развитие)MIR (Modernization. Innovation. Research)2079-46652411-796XSchool of Public Administrationmir-91Research ArticleРАЗВИТИЕRESEARCHРЕГУЛИРОВАНИЕ РЫНКА ЛЕКАРСТВЕННЫХ СРЕДСТВ: ЗАРУБЕЖНЫЙ ОПЫТTHE REGULATION OF THE MARKET FOR PHARMACEUTICALS: FOREIGN EXPERIENCEГришинД. Л.GrishinD. L.

Аспирант

redfox1312@mail.ruМосковская международная высшая школа бизнеса МИРБИС (Институт), МоскваРоссияThe Moscow International Higher Business School MIRBIS, MoscowRussian Federation20131109201541(13)116119Copyright © Гришин Д.Л., 20152015Гришин Д.Л.Grishin D.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.mir-nayka.com/jour/article/view/91

В статье рассмотрен вопрос о регулировании рынка лекарственных средств в подходах иностранных ученых. Именуются три основных направления такого регулирования: политические задачи, регулирующие институты и способы регулирования, из которых наиболее полно исследованы задачи и способы регулирования

In article the question of regulation of the market of medicines in approaches of foreign scientists is considered. Three main lines of such regulation are named: the political tasks regulating institutes and ways of regulation, from which tasks and ways of regulation are most fully studied. 

лекарствалекарственные средстварынокрынок лекарственных средстврегуляторрегуляциярегулятор рынка лекарственных средствdrugmarketdrugs marketregulatorregulationdrugs market regulatorReferencesMaynard A. and K. Bloor Regulating the Pharmaceutical Industry, British Medical Journal 315 (26 July 1997), рр. 200–201Maynard A. and K. Bloor Regulating the Pharmaceutical Industry, British Medical Journal 315 (26 July 1997), рр. 200–201Danzon Patricia M. Economics of the Pharmaceutical Industy. NBER Reporter: Research Summary Fall 2006.Danzon Patricia M. Economics of the Pharmaceutical Industy. NBER Reporter: Research Summary Fall 2006.Organization for Economic Cooperation and Development, OECD Health Data 2009. Paris: OECD, 2009.Organization for Economic Cooperation and Development, OECD Health Data 2009. Paris: OECD, 2009.Bloor K.E., Maynard A.K., and Freemantle N. Lessons from International Experience in Controlling Pharmaceutical Expenditure III: Regulating Industry // British Medical Journal 313 (6 July 1996): 33–35.Bloor K.E., Maynard A.K., and Freemantle N. Lessons from International Experience in Controlling Pharmaceutical Expenditure III: Regulating Industry // British Medical Journal 313 (6 July 1996): 33–35.Medical Outcomes Trust, SF-36.com home page,www.sf36.com (20 February 2003); and Euro Qol Group, EQ 5D home page, www. euroqol.org (20 February 2003)Medical Outcomes Trust, SF-36.com home page,www.sf36.com (20 February 2003); and Euro Qol Group, EQ 5D home page, www. euroqol.org (20 February 2003)Alan Maynard and Karen Bloor Dilemmas In Regulation Of The Market For Pharmaceuticals. Health Affairs on September 24, 2012, pp. 31-41.Alan Maynard and Karen Bloor Dilemmas In Regulation Of The Market For Pharmaceuticals. Health Affairs on September 24, 2012, pp. 31-41.Drug access by country, WHO (World Health Organization). Correspondence on access to essential drugs. Department of Essential Drugs and Medecines Policy. Geneva, 2010.Drug access by country, WHO (World Health Organization). Correspondence on access to essential drugs. Department of Essential Drugs and Medecines Policy. Geneva, 2010.Bloor K.E. and N. Freemantle Lessons from International Experience in Controlling Pharmaceutical Expenditure I: Influencing Patients, British Medical Journal 312 (8 June 1996): 1469–1471. Freemantle N. and K.E. Bloor, Lessons from International Experience in Controlling Pharmaceutical Expenditure II: Influencing Doctors, British Medical Journal 312 (15 June 1996): 1525–1527.Bloor K.E. and N. Freemantle Lessons from International Experience in Controlling Pharmaceutical Expenditure I: Influencing Patients, British Medical Journal 312 (8 June 1996): 1469–1471. Freemantle N. and K.E. Bloor, Lessons from International Experience in Controlling Pharmaceutical Expenditure II: Influencing Doctors, British Medical Journal 312 (15 June 1996): 1525–1527.B. O’Brien, The Effect of Patient Charges on the Utilisation of Prescription Medicines, Journal of Health Economics 8, no. 1, 1999, рр. 109–132;B. O’Brien, The Effect of Patient Charges on the Utilisation of Prescription Medicines, Journal of Health Economics 8, no. 1, 1999, рр. 109–132;Office of Fair Trading, Price Fixing of Medicaments Ends, Press Release, London: OFT, 15 May 2001; Europe on the Brink of Direct-to-Consumer Advertising. Editorial, Lancet 359, no. 9319, 2002, р. 1709.Office of Fair Trading, Price Fixing of Medicaments Ends, Press Release, London: OFT, 15 May 2001; Europe on the Brink of Direct-to-Consumer Advertising. Editorial, Lancet 359, no. 9319, 2002, р. 1709.Petersen M. Heartfelt Advice, Hefty Fees, New York Times, 11 August 2002.Petersen M. Heartfelt Advice, Hefty Fees, New York Times, 11 August 2002.Bradlow J. and A. Coulter Effect of Fundholding and Indicative Prescribing Schemes on General Practitioners’ Prescribing Costs, British Medical Journal 307, 2003 рр. 1186–1189.Bradlow J. and A. Coulter Effect of Fundholding and Indicative Prescribing Schemes on General Practitioners’ Prescribing Costs, British Medical Journal 307, 2003 рр. 1186–1189.Giuffrida A. and D. Torgerson Should We Pay the Patient? Review of Financial Incentives to Enhance Patient Compliance, British Medical Journal 315, 20 September 1997, рр. 703–707.Giuffrida A. and D. Torgerson Should We Pay the Patient? Review of Financial Incentives to Enhance Patient Compliance, British Medical Journal 315, 20 September 1997, рр. 703–707.

The authors declare that there are no conflicts of interest present.